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WHAT MATTERS IS MORE THAN JUST THE
CHOICE OF PHARMACEUTICAL AGENT
Any model to guide the choice of agonist substitute drugs for
substance misusers must reﬂect the heterogeneity of the
treatment population as well as the pharmacodynamics and
pharmacokinetics of the proposed agents. Even in the face of
compelling evidence of clinical effectiveness, as is seen in the
case of opioid replacement, the stigmatization of substance
misusers by society reduces drug development and
consequently the availability of valuable substitution
therapies.
Darke & Farrell propose a framework to determine the suit-
ability of agonist maintenance as a treatment option for
problems involving the main classes of psychoactive drug
[1]. They conclude that there is a strong case for agonist
maintenance in opioid dependency—especially in the case
of long-acting drugs that match closely the authors’ frame-
work. They also propose that there is a place for substitu-
tion treatment in nicotine dependency. Their framework
does not, however, support a maintenance role in the other
drug classes.
The model proposed would be enhanced by consid-
eration of additional key variables which may inﬂu-
ence clinical outcomes. The pharmacokinetics and
pharmacodynamics of drugs are important factors,
differing greatly for the same medication given orally,
as long-acting depot or as intravenous injection.
Clearly, the neuropharmacological effects and subjective
experience of taking such medications are affected not
only by the drug chosen (and its mechanism of
action), but also by the way it is taken. Some
agents/routes of ingestion will give rapid and
pronounced initial effects which some patients will
value as approximating to their experiences with
their chosen drug of misuse. Others will have less
rapid initial peak effects, but deliver a more
protracted clinical effect. This will inﬂuence suitabil-
ity as a substitution agent.
Also, the clinical value of these treatments reﬂects
individual patient circumstances and context. Sub-
stance misusers are a heterogeneous group, often hav-
ing complex drug histories and comorbid
psychological difﬁculties, in challenging social circum-
stances. Matching an individual to a speciﬁc drug
must take this into account. Indeed, as an individual
responds to treatment the clinical approach, as well
as preferred agent to meet their clinical circum-
stances, may change. As a result there are some
agents available for opioid dependency which meet
the proposed criteria less fully but may still be clini-
cally valuable in speciﬁc circumstances. Diamorphine,
for example, has developed an evidence base demon-
strating clinical effectiveness in speciﬁc circumstances
which mitigates against their lack of a ‘match’ to the
proposed model [2]. This model must be modiﬁed to
reﬂect these variables more clearly.
Unfortunately, even in the case of opioids, the
menu of agents available remains limited. A paucity
of drug development since methadone reached promi-
nence as a substitution agent has limited the ability to
reﬁne treatments to match patient need. In the United
Kingdom, only one new opioid substitution therapy
(OST) has become licensed for use in the last 20 years,
despite the extent and consequences of opioid depen-
dency. Systematic reviews have consistently shown
OST to be highly cost-effective [3], but this has not
increased drug development activity in the pharma-
ceutical industry. This reluctance may reﬂect society’s
stigmatisation of the substance misuse population [4].
The use of OST is constantly challenged politically and
through the media [4,5]. This cultural opposition to
substitution therapy—even when treatments meet ob-
jective criteria as appropriate agonist agents and enjoy
a strong evidence base for harm reduction—suggests
that we have not yet won the battle in the public
© 2016 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction, 111, 775–782
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in
any medium, provided the original work is properly cited, the use is non-commercial and no modiﬁcations or adaptations are made.
Commentaries 779
debate regarding the beneﬁts of this treatment ap-
proach. An unhelpful polarity exists between (mainly
psychosocial) interventions, targeting immediate absti-
nence and pharmacological substitution treatments,
promoting stabilization and harm reduction. In reality,
both are required to tackle this complex biopsychosocial
condition, and better research into whole treatment sys-
tems combining both approaches is required [6,7]. This
situation also results in limited availability of treatment
options to address clinical challenges. If more opportu-
nity for development of useful agents was offered, the
ﬁeld could move on to address speciﬁc criticisms, such
as the lack of strong evidence for achieving more ambi-
tious recovery outcomes or the limited treatments avail-
able to meet individuals’ needs.
Finally, it must be recognized that potential cases exist
for agonist prescribing in other drug classes—for example,
benzodiazepines [8] or amphetamines [9]. No such agents
currently meet the proposed criteria, but some are never-
theless being used pragmatically in clinical practice despite
a lack of evidence to support this. This is not unlike the
clinical circumstances that saw the genesis of OST in the
face of HIV. Here again, there is a need for programmes of
clinical research to explore more effectively the potential
beneﬁts of these treatments.
The proposed framework [1] is a helpful ﬁrst step when
considering potential pharmaceutical treatments for sub-
stance misuse, but the model addresses only part of the
story. Clinicians will continue to be faced with people
who put themselves at risk and for whom current
evidence-based interventions do not help. More high-
quality research is needed reﬂecting the heterogeneity
of the substance misusing population. Even when the clin-
ical evidence base is compelling, cultural/socio-political
issues still drive stigma and a reluctance to progress this
type of clinical care. It is important that clinicians and
scientists continue to articulate clearly the complexity
of this population, as well as the evidence that we can
reduce signiﬁcantly the negative impacts of illicit sub-
stance use.
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RESPONSE TO COMMENTARIES ON ‘WHICH
MEDICATIONS ARE SUITABLE FOR AGONIST
DRUG MAINTENANCE’
As the commentators note, treatment refractory substance
use disorders are a clinical reality, and pharmacological
intervention is, for many patients, a clinical necessity.
Criteria to deﬁne what constitutes an appropriate agonist
are essential. We are gratiﬁed that the commentators found
this to be ‘a helpful ﬁrst step’ in this endeavour.
We thank the commentators for their considered com-
ments on our For Debate piece addressing agonist main-
tenance [1]. In our opinion, the For Debate series
provides a valuable platform for open discussion of clin-
ical issues without the constraints of a formal compre-
hensive review. It is our hope that this piece, and the
associated commentaries, do indeed encourage debate
and research in this crucial ﬁeld. It should be noted that
the issue of maintenance is not unique to this ﬁeld, but
also applies to medications such as antidepressants. We
value clear recognition, and understanding, of a patient
population that requires sustained medication for their
chronic condition.
Kidd and colleagues [2] describe the work as ‘a helpful
ﬁrst step’, which is exactly what we intended. Our aim
was not to be prescriptive, but to engender further
discourse on the role of maintenance across substances.
As noted by Lingford-Hughes [3], long-term maintenance
is not employed widely outside the opioids and, to a lesser
extent, nicotine. Furthermore, as Kidd and colleagues [2]
note, even within opioids the agonist treatment palette
remains limited. The clinical reality is that, as argued by
Shoptaw [4] and Walter & Soyka [5], abstinence is not al-
ways a feasible treatment goal. Treatment-refractory
substance use disorders are a clinical reality, and pharma-
cological intervention is, for many patients, a clinical ne-
cessity [6].
Not all drugs appear appropriate for agonist main-
tenance and, as we have argued, the characteristics
of some drug classes may well preclude maintenance.
Only research will tell. Cannabis and the benzodiaze-
pines, however, appear ripe for such work, but we
must have criteria to deﬁne our understanding of
what constitutes an appropriate maintenance agonist.
There are a plethora of issues to be examined, many
of which are raised in the commentaries, that in-
cludes a better understating of drugs and brain
chemistry, pharmacokinetics, pharmacodynamics and
route of administration. We look forward to the
debate, and to new research advancing our treat-
ment options. We do hope all this contributes to
the development of new treatment agents which
show demonstrable treatment beneﬁt and help us to
move forward in the development of addiction treat-
ment technology.
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